Selank is a synthetic heptapeptide constructed from the tetrapeptide tuftsin, a fragment of the immunoglobulin G heavy chain, extended with a proline-glycine-proline sequence intended to increase stability. It was developed at the Institute of Molecular Genetics in Russia and is studied in the literature primarily as an anxiolytic research compound.
Mechanistic context
The proposed mechanism differs from that of conventional anxiolytics. Rather than acting directly at GABA-A receptors in the manner of benzodiazepines, the published work examines effects on enkephalin-degrading enzymes, with the implication that Selank modulates endogenous opioid peptide availability. A separate line of enquiry concerns brain-derived neurotrophic factor expression. The tuftsin origin also connects the peptide to immunomodulatory activity, though this is less developed in the cited literature.
Published findings
Zozulya and colleagues (2001) reported the inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of anxiolytic activity — the principal mechanistic proposal in this literature.
Zozulia and colleagues (2008) reported on efficacy and possible mechanisms in the therapy of generalised anxiety disorders and neurasthenia, published in a Russian-language psychiatric journal. Kasian and colleagues (2017) reported that Selank enhanced the effect of diazepam in reducing anxiety under unpredictable chronic mild stress conditions in rats — a combination design that positions the peptide relative to an established comparator rather than against vehicle alone.
Kolik and colleagues (2019) reported protection against ethanol-induced memory impairment in rats, with BDNF content in the hippocampus and prefrontal cortex measured as the proposed mediating variable.
Scope and limitations of the evidence
The Selank literature is concentrated among Russian research institutions, and a portion appears in Russian-language journals. This has practical consequences: peer review conventions, trial registration and reporting standards differ across publishing traditions, and independent replication outside that research community is limited. The 2008 clinical report should be read with these constraints in view.
The rodent work is more accessible to independent evaluation. The unpredictable chronic mild stress model used by Kasian and colleagues is an established paradigm but is known for variable reproducibility across laboratories, which affects the weight any single report can carry.
Use in experimental design
Anxiety-like behaviour in rodents is measured through paradigms — elevated plus maze, open field, light-dark box — that are sensitive to handling, lighting, time of day and prior stress exposure. These should be documented explicitly. Where BDNF is measured as a mediator, the distinction between transcript and mature protein matters, as does brain region, since the Kolik work reports region-specific findings rather than a global change.
Analytical and handling notes
Each lot is supplied with a certificate of analysis reporting RP-HPLC purity, mass identification by ESI-MS and label claim recovery, together with an independent ICP-MS elemental impurities report. Purity figures apply to the specific lot tested and should be read against the lot documentation rather than inferred from generic reference material. Storage guidance appears on the technical data sheet; the exact supplied salt form, counterion and hydration state are lot and supplier specific and should be reconciled against supplier documentation before quantitative work.
This material is supplied for laboratory research use only. It is not a drug, is not intended for human or veterinary use, and no statement above should be read as a claim of therapeutic effect.
